Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other financing activities (2020 - 2022)

Ovid Therapeutics (OVID) has disclosed Other financing activities for 3 consecutive years, with -$56943.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Other financing activities changed N/A year-over-year to -$56943.0, compared with a TTM value of $56943.0 through Sep 2022, down 72.03%, and an annual FY2021 reading of $21314.0, down 86.94% over the prior year.
  • Other financing activities was -$56943.0 for Q4 2022 at Ovid Therapeutics, down from $41023.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $182236.0 in Q4 2020 and bottomed at -$56943.0 in Q4 2022.
  • Average Other financing activities over 3 years is $26366.3, with a median of $15920.0 recorded in 2022.
  • Peak annual rise in Other financing activities hit 215.55% in 2021, while the deepest fall reached 215.55% in 2021.
  • Year by year, Other financing activities stood at $182236.0 in 2020, then crashed by 88.3% to $21314.0 in 2021, then plummeted by 367.16% to -$56943.0 in 2022.
  • Business Quant data shows Other financing activities for OVID at -$56943.0 in Q4 2022, $41023.0 in Q3 2022, and $15920.0 in Q2 2022.